Margolin S, Bengtsson N-O, Carlsson L, Edlund P, Hellstrøm M, Karlsson P, et al. A randomised feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer. AO [Internet]. 2011 Jan. 1 [cited 2025 Feb. 21];50(1):35-41. Available from: https://medicaljournalssweden.se/actaoncologica/article/view/31806